Brand Name Prescription Drugs Antitrust Litigation, In re

Decision Date31 July 1997
Docket NumberNos. 96-2233,96-2486,96-2483,96-2878 and 96-2904,96-2460,96-2484,96-2813,96-2459,s. 96-2233
Citation115 F.3d 456
Parties1997-1 Trade Cases P 71,819, 37 Fed.R.Serv.3d 798 In re BRAND NAME PRESCRIPTION DRUGS ANTITRUST LITIGATION.
CourtU.S. Court of Appeals — Seventh Circuit

Mart Vehik, McMath Law Firm, P.A., Little Rock, AR, David Price, Woodward & Epley, Magnolia, AR, Bryan Hosto, Hosto Law Firm, Little Rock, AR (submitted), for Plaintiff-Appellant Lawrence Adams dba McSpadden Drug Store, Boyce Arnett dba Medical Center Pharmacy, City Pharmacy Little Rock, Rosedale Pharmacy Incorporated, Park West Pharmacy, Incorporated.

Joel G. Chefitz (submitted), Katten, Muchin & Zavis, Chicago, IL, for Defendant-Appellee American Home Products Corporation, American Cyanamid Company in No. 96-2813.

Joel G. Chefitz, Katten, Muchin & Zavis, Chicago, IL, Thomas P. Sullivan, Richard T. Franch, Jenner & Block, Chicago, IL, Stephen S. Madsen, Douglas D. Broadwater, Cravath, Swaine & Moore (submitted), New York City, for Defendants-Appellees American Home Products Corporation, Bristol-Meyer Company in Nos. 96-2878, 96-2904.

Before POSNER, Chief Judge, and BAUER and DIANE P. WOOD, Circuit Judges.

POSNER, Chief Judge.

Pending in the district court is an antitrust class action on behalf of pharmacies all over the United States against twenty-four manufacturers, and seven wholesalers, of pharmaceuticals. The class was certified under Fed.R.Civ.P. 23(b)(3). A number of class members opted out of the class action and brought their own suits against the manufacturers, but did not name the wholesalers as defendants. The district judge granted summary judgment for the wholesaler defendants in the class action and entered a final, appealable judgment in their favor under Fed.R.Civ.P. 54(b), precipitating appeals by some of the opt-out plaintiffs and also by some of the class members who are not named plaintiffs in the class action. The wholesalers ask us to dismiss these appeals on the ground that the appellants, not being parties to the class action, have no right to appeal from a judgment entered in it.

We begin with the opt-outs. Having opted out of the class action, they were no longer members of the class and so in no sense were parties. A nonparty has no right to appeal. Marino v. Ortiz, 484 U.S. 301, 304, 108 S.Ct. 586, 587-88, 98 L.Ed.2d 629 (1988) (per curiam). If he wants to have that right, he should intervene in the district court, id., since an intervenor has the rights of a party (is a party), including the right to appeal. If the district court denies the motion to intervene, the disappointed movant can appeal that denial.

Now it is true that the opt-outs were permitted to participate in the pretrial proceedings in the class action by attending depositions, responding to requests for discovery, and answering the wholesalers' motion for summary judgment. But their participation was authorized in a pretrial order that expressly denied that these participants were to be deemed parties; the purpose of allowing their participation was merely to facilitate the coordination of the opt-outs' parallel suits with the class action. (We have not been informed why the Multidistrict Litigation Panel did not consolidate the pretrial proceedings in the parallel suits with the pretrial proceedings in the class action.) The opt-outs argue that the judgment in favor of the wholesalers will affect them even though they have not sued the wholesalers. It will not have a preclusive effect on them, because they are neither parties, nor in privity with any parties, to the class action. Maybe it will affect their interests enough in some other way to permit them to intervene in the class action--we cannot tell on the record before us. Although it would be peculiar for an opt-out to seek to opt back in, this is occasionally sought and allowed. E.g., In re Electric Weld Steel Tubing Antitrust Litigation, 1982-2 Trade Cases (CCH) para. 64872 (E.D.Pa.1982); 3 Herbert B. Newberg & Alba Conte, Newberg on Class Actions § 16.18, p. 16-99 (3d ed.1992).

But a request for intervention must be addressed to the district court. Although some cases have allowed nonparties to appeal without first intervening in the district court, this bypass is no longer permissible after Marino. See also SEC v. Wozniak, 33 F.3d 13 (7th Cir.1994). The present case shows the wisdom of this approach. Here we have some 163 claimants who having exercised their right to exit from the case in the district court now wish to come charging back in on appeal. We would be facing a veritable avalanche of appeals if all opt-outs could appeal from any appealable judgment in the action.

So much for the opt-outs; as for the class members (some 90 in number) who want to appeal even though they are not named plaintiffs, to allow them to appeal would be an even worse affront to intelligent judicial administration because it would fragment the control of the class action....

To continue reading

Request your trial
23 cases
  • Day v. Persels
    • United States
    • U.S. Court of Appeals — Eleventh Circuit
    • 10 September 2013
    ... ... Kirkpatrick, Public Citizen Litigation Group, Washington, DC, Altom M. Maglio, Maglio ... [a] party to an action is a person whose name is designated on record as plaintiff or ... In re Cement Antitrust Litig., 688 F.2d 1297, 1310 (9th Cir.1982) ... the litigation, Williams cites In re Brand Name Prescription Drugs Antitrust Litigation, ... ...
  • Williams v. General Elec. Capital Auto Lease, Inc.
    • United States
    • U.S. Court of Appeals — Seventh Circuit
    • 27 November 1998
    ... ... (whether the result of full-blown litigation or settlement) to bind both sides in the absence ... See, e.g., In re Brand Name Prescription Drugs Antitrust Litig., 115 ... ...
  • Culver v. City of Milwaukee
    • United States
    • U.S. Court of Appeals — Seventh Circuit
    • 15 January 2002
    ... ... -Up Truck Fuel Tank Products Liability Litigation, 55 F.3d 768, 801-05 (3d Cir. 1995); Weinberger ... , Ltd., supra, 204 F.3d at 760; In re Brand Name Prescription Drugs Antitrust Litigation, 115 ... ...
  • Litvak v. Scylla Properties, LLC
    • United States
    • Florida District Court of Appeals
    • 21 December 2006
    ... ... interests were aligned in the litigation; and that class counsel included the lawyer who ... , and without any specific procedural prescription for making their position known to the trial ... See In re Brand Name Prescription Drugs Antitrust Litig., 115 ... ...
  • Request a trial to view additional results
4 books & journal articles
  • Table of Cases
    • United States
    • ABA Antitrust Library Pharmaceutical Industry Antitrust Handbook. Second Edition
    • 8 December 2018
    ...Drugs Antitrust Litig., In re , 186 F.3d 781 (7th Cir. 1999), 385, 386 Brand Name Prescription Drugs Antitrust Litig., In re , 115 F.3d 456 (7th Cir. 1997), 385 Brand Name Prescription Drugs Antitrust Litig., In re , 123 F.3d 599 (7th Cir. 1997), 385 Brand Name Prescription Drugs Antitrust ......
  • Indirect Purchaser Settlements
    • United States
    • ABA Antitrust Library Indirect Purchaser Litigation Handbook. Second Edition
    • 5 December 2016
    ...newspaper would suffice despite not being as effective as individual notice). 128 . In re Brand Name Prescription Drugs Antitrust Litig., 115 F.3d 456, 457 (7th Cir. 1997). Plaintiffs who opt out can attempt to intervene in the action and thereby regain the rights of a party, including the ......
  • Table of cases
    • United States
    • ABA Antitrust Library Indirect Purchaser Litigation Handbook. Second Edition
    • 5 December 2016
    ...Ill. 1973), 63, 450 Boyle v. Giral, 820 A.2d 561 (D.C. 2003), 33, 289, 296, 299 Brand Name Prescription Drugs Antitrust Litig., In re, 115 F.3d 456 (7th Cir. 1997), 301 Brand Name Prescription Drugs Antitrust Litig., In re, 123 F.3d 599 (7th Cir. 1997), 16, 18, 38, 39 Brand Name Prescriptio......
  • Antitrust Issues in the Distribution of Pharmaceutical Products
    • United States
    • ABA Antitrust Library Pharmaceutical Industry Antitrust Handbook. Second Edition
    • 8 December 2018
    ...Name Prescription Drugs Antitrust Litig., 1996 WL 167350, at *20 (N.D. Ill. 1996); In re Brand Name Prescription Drugs Antitrust Litig., 115 F.3d 456 (7th Cir. 1997); In re Brand Name Prescription Drugs Antitrust Litig., 123 F.3d 599 (7th Cir. 1997); In re Brand Name Prescription Drugs Anti......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT